Newly Public Allurion Aims to Show How Med Tech Can Complement Obesity Drugs
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs. The post Newly Public Allurion Aims to Show How Med Tech Can Complement Obesity Drugs appeared first on MedCity News.
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
The post Newly Public Allurion Aims to Show How Med Tech Can Complement Obesity Drugs appeared first on MedCity News.
